Both brand and generic drug labels should reflect updated information on known safety risks, but currently only brand manufacturers are able to initiate this change.

Women need updated safety and efficacy information to make informed health care decisions for themselves and their families.

Generic drugs dominate the market and women deserve the same legal protections regardless of which drug they are prescribed.

Join the conversation!
#samedrugsametestandards
#genericsmatter4women

What will the proposed rule do?

- Gives generic drug manufacturers authority to initiate safety label changes through Changes Being Effected (CBE) process
- Provides a framework to ensure consistency between bioequivalent brand and generic drug labels
- Requires brand and generic manufacturers to update their labels within 30 days after a CBE supplement has been approved

The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We bring the voices of women consumers to policy and regulatory decision-making bodies. We are supported by our members and do not take financial contributions from drug companies, medical device manufacturers, insurance companies, or any other entity with a financial stake in women’s health decision-making.